

S1.06 Post-operative residual tumour

Not stated

Absent

Present Details:

G1.09 Surgeon's specific remarks

Macroscopic findings

S2.04 Lymph nodes

SITE 1

--

Description

Total number of nodes

--

Max. diameter/ size range

	mm	to		mm
--	----	----	--	----

SITE 2

--

Description

Total number of nodes

--

Max. diameter/ size range

	mm	to		mm
--	----	----	--	----

SITE 3

--

Description

SITE 3 Total number of nodes

--

Max. diameter/ size range

	mm	to		mm
--	----	----	--	----

SITE 4

--

Description

Total number of nodes

--

Max. diameter/ size range

	mm	to		mm
--	----	----	--	----

SITE 5

--

Description

Total number of nodes

--

Max. diameter/ size range

	mm	to		mm
--	----	----	--	----

SITE 6

--

Description

Total number of nodes

--

Max. diameter/ size range

	mm	to		mm
--	----	----	--	----

SITE 7

Description

Total number of nodes

Max. diameter/ size range

 mm to mm**S2.05 Omentum**

Dimensions

 length mm x width mm x thickness mm

Proportion of fat replaced by tumour

 % est.

Description

S2.06 Peritoneal biopsies**SITE 1**

Dimensions

 length mm x width mm x thickness mm

Description

SITE 2

Dimensions

 length mm x width mm x thickness mm

Description

SITE 3**SITE 3** Dimensions length mm x width mm x thickness mm

Description

S2.07 Ovaries**Left Ovary**

Surface

Dimensions

 length mm x width mm x thickness mm

Description

Right Ovary

Surface

Dimensions

 length mm x width mm x thickness mm

Description

S2.08 Fallopian tubes**Left fallopian tube**

Dimensions

(Length x max. diameter)

 length mm x diameter mm

Description

Right fallopian tube

Dimensions

(Length x max. diameter)

 length mm x diameter mm

Distance of cervical tumour from the inferior surgical margin

 mm

Max. depth of cervical wall invasion

 mm

Thickness of normal (uninvolved) cervical wall

 mm

G2.06 Other relevant macroscopic comment

Microscopic findings

S3.01 Lymph node involvement by tumour

SITE 1

Number of nodes involved by tumour

Total number of nodes resected

Max. dimension of the metastasis or size range

 mm to mm

Extranodal spread

Absent

Present

SITE 2

Number of nodes involved by tumour

Total number of nodes resected

Max. dimension of the metastasis or size range

 mm to mm

Extranodal spread

Absent

Present

SITE 3

Number of nodes involved by tumour

Max. dimension of the metastasis or size range

 mm to mm

Extranodal spread

Absent

Present

SITE 4

Number of nodes involved by tumour

Total number of nodes resected

Max. dimension of the metastasis or size range

 mm to mm

Extranodal spread

Absent

Present

SITE 5

Number of nodes involved by tumour

Total number of nodes resected

Max. dimension of the metastasis or size range

 mm to mm

Extranodal spread

Absent

Present

SITE 6

Number of nodes involved by tumour

SITE 6 Continued

Total number of nodes resected

Max. dimension of the metastasis or size range

 mm to mm

Extranodal spread

- Absent
Present

SITE 7

Number of nodes involved by tumour

Total number of nodes resected

Max. dimension of the metastasis or size range

 mm to mm

Extranodal spread

- Absent
Present

S3.02 Omental involvement:

- Tumour free
Involved

Nature of involvement:

S3.03 Peritoneal involvement:

- Tumour free
Involved

Nature of involvement:

S3.04 Ovarian involvement:

- Tumour free
Involved

Nature of involvement:

S3.05 Fallopian tubal involvement

- Tumour free
Involved

Nature of involvement:

S3.06 Histological tumour type

- Endometrioid adenocarcinoma
and variant
Mucinous adenocarcinoma
Serous carcinoma
Clear cell carcinoma
Carcinosarcoma
Undifferentiated carcinoma
Other Tumour Type

Mixed types of endometrial carcinomas (state all and relative percentages)

and

and

S3.07 Histological grade for endometrioid carcinomas:

FIGO

- Grade 1
Grade 2
Grade 3
Grading not applicable

Other grading system

G3.02 Year of publication of grading system

S3.08 Maximum microscopic depth of myometrial invasion

 mm

(in histologic slide No: _____)

Normal myometrial wall thickness

 mm

S3.09 Lymphovascular invasion

Absent

Present

At the tumour interface

Remote to the tumour interface

Max. distance from tumour face

mm

S3.10 Cervical involvement:

Involvement of cervical mucosa only

Absent

Present & in-continuity

Present & separate

Involvement of cervical stroma

Absent

Present in-continuity

separate

Maximum invasive depth

mm

(in histologic slide No: _____)

Normal cervical wall thickness

mm

Cervical vascular involvement

Absent

Present

S3.11 Residual non-tumourous endometrium

Atrophic/cycle phase

Hyperplastic

Atypical hyperplastic

Description (eg polyps)

In situ carcinoma:

Absent

Present

Multicentric/multifocal carcinoma:

Absent

Present

Histological type

Extent

Sites

G3.03 Other relevant microscopic comment

Ancillary test findings

G4.01 Histochemical stains

G4.02 Immunohistochemical stains

Positive Abs	<input type="text"/>
Negative Abs	<input type="text"/>
Equivocal Abs	<input type="text"/>

Interpretation

Clinical significance

Synthesis and overview

S5.01 Tumour stage FIGO (see p8)

Pathological tumour stage (pTNM)**

T

N

M

S5.02 Year of publication and edition of cancer staging system

G5.01 Residual tumour status

RX

R0

R1

R2

G5.02 Diagnostic summary

Include: operative procedure/specimen type; tumour type and stage; residual tumour status

S5.03 Other relevant comments

Tumour stage FIGO & pTNM##

Primary Tumour (T) (Surgical-Pathologic Findings)		
TNM	FIGO	
TX		Primary tumour cannot be assessed
T0		No evidence of primary tumour
Tis*		Carcinoma in situ (preinvasive carcinoma)
T1	I	Tumour confined to corpus uteri
T1a	IA	Tumour limited to endometrium or invades less than one-half of the myometrium
T1b	IB	Tumour invades one-half or more of the myometrium
T2	II	Tumour invades stromal connective tissue of the cervix but does not extend beyond uterus**
T3a	IIIA	Tumour involves serosa and /or adnexa (direct extension or metastasis)
T3b	IIIB	Vaginal involvement (direct extension or metastasis) or parametrial involvement.
T4	IVA	Tumour invades bladder mucosa and /or bowel mucosa (bullous oedema is not sufficient to classify a tumour as T4)
Regional Lymph Nodes (N)		
NX		Regional lymph nodes cannot be assessed
N0		No regional lymph node metastasis
N1	IIIC1	Regional lymph nodes metastasis to pelvic lymph nodes
N2	IIIC2	Regional lymph nodes metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes.
Distant Metastasis (M)		
M0		No distant metastasis
M1	IVB	Distant metastasis (includes metastasis to inguinal lymph nodes intraperitoneal disease, or lung, liver, or bone. It excludes metastasis to para-aortic lymph nodes, vagina, pelvic serosa, or adnexa.

* Note: FIGO no longer includes Stage 0(Tis)

** Endocervical glandular involvement only should be considered Stage I and not as Stage II.

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science and Business Media LLC, www.springerlink.com.

Worksheet prepared by:

On: